Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · Real-Time Price · USD
5.97
-0.22 (-3.55%)
Jan 31, 2025, 4:00 PM EST - Market closed
Y-mAbs Therapeutics Employees
Y-mAbs Therapeutics had 100 employees as of December 31, 2023. The number of employees decreased by 47 or -31.97% compared to the previous year.
Employees
100
Change (1Y)
-47
Growth (1Y)
-31.97%
Revenue / Employee
$845,530
Profits / Employee
-$238,640
Market Cap
267.39M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
YMAB News
- 1 day ago - Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting - GlobeNewsWire
- 7 days ago - Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials - Seeking Alpha
- 22 days ago - Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities - GlobeNewsWire
- 22 days ago - Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit - GlobeNewsWire
- 22 days ago - Y-mAbs Provides Strategic Business Update and 2025 Priorities - GlobeNewsWire
- 5 weeks ago - Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting - GlobeNewsWire
- 2 months ago - Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference - GlobeNewsWire